Werth V, Pike M, Merrill J, Morand E, van Vollenhoven R, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. J of Skin [Internet]. 2023Mar.13 [cited 2024Jul.3];7(2):s114. Available from: https://jofskin.org/index.php/skin/article/view/1964